Best Neurology Companies in New Jersey, United States
The 49 best Neurology companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: PTC Therapeutics.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics Developer of small molecule drugs for the treatment of rare diseases | $248M | 38 mo ago | 995 995 → 1,159 (+16%) | — | 1,951 patents Small-molecule therapeutics for neurodegenerative and metabolic genetic disorders | — |
| 2 | Tris Pharma Innovating transformative treatments for ADHD, pain, and CNS disorders | $125M | 35 mo ago | 441 441 → 503 (+14%) | Ketan Mehta Founder & CEO | 217 patents Extended-release oral dosage forms, especially gastro-retentive floating/raft drug delivery systems. | 1 partnership |
| 3 | ElectroCore Developer of non-invasive vagus nerve stimulation devices 62Funding top 20%Patents top 20%Product top 24%Innovation top 26% All 12 signals ▾Fundingtop 20% Patentstop 20% Producttop 24% Innovationtop 26% Techtop 42% Talenttop 42% Moattop 43% Fin. healthtop 47% Marketbottom 49% Globalbottom 49% Growthbottom 47% Newsbottom 41% Funding: Raised $121M across 13 rounds · 13 rounds over 14 yrs (0.9/yr) Patents: 518 patents matched (strict assignee match) · 124 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $121M | 10 mo ago | 58 58 → 98 (+69%) | JP Errico Founder | 516 patents Implantable and external nerve stimulation devices for therapeutic neuromodulation | — |
| 4 | edge therapeutics Edge Therapeutics, a biotechnology company, transforms FDA-approved drugs into therapies that address unmet… | $106M | 120 mo ago | 9 | — | — | — |
| 5 | Pacira Developer of injectable non-opioid products for post-surgical pain control | $85M | 113 mo ago | 712 | — | — | — |
| 6 | Engage Therapeutics Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | $31M | 81 mo ago | 7 | — | — | — |
| 7 | Nautilus Neurosciences Develops drugs for neurological disorders | $26M | 196 mo ago | 22 | — | — | — |
| 8 | DiamiR Developer of minimally invasive diagnostic tests | $22M | 15 mo ago | 13 | — | 55 patents miRNA biomarker assays for diagnosing and monitoring Parkinson's and other neurodegenerative diseases | — |
| 9 | Protega Pharmaceuticals Provider of specialty pharmaceutical company that focuses on responsible pain management | $16M | 15 mo ago | — | Stefan Aigner CEO | — | — |
| 10 | Somnus Therapeutics Online entertainment arena offering diverse games, community features, and digital empowerment | $15M | 197 mo ago | 4 | Gary Cupit CEO | — | — |
| 11 | JOGO Developer of digital therapeutics for neuromuscular conditions | $12M | 14 mo ago | 2 | Sanjai Murali Founder & CEO | — | — |
| 12 | Silo Pharma Manufacturer of neurological drugs | $10M | 26 mo ago | 2 | Eric Weisblum Founder & CEO | — | — |
| 13 | Aquestive Therapeutics Developer of small molecule-based therapeutics for the treatment of CNS diseases | $9M | 11 mo ago | 285 285 → 151 (-47%) | Daniel Barber Chief Executive Officer | 213 patents Advanced drug delivery films for epinephrine and prodrugs, oral and topical dosing | 4 job openings |
| 14 | Durin Technologies Developer of the diagnostic test for neurodegenerative diseases | $8M | 33 mo ago | 5 | Benjamin Belinka Co-Founder | — | — |
| 15 | Grace Therapeutics Developer of intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage | $7M | 34 mo ago | — | Prashant Kohli CEO & Director | — | — |
| 16 | PaxMedica Developer of drugs for treating neurodevelopmental disorders | $3M | 42 mo ago | 3 | Howard Weisman Chairman and CEO | 29 patents Intranasal antipurinergic drug delivery for treating nervous system disorders | — |
| 17 | Intellect Neurosciences Discovery and development of Proteinopathies | $3M | 195 mo ago | 1 | Elliot Maza CEO | 62 patents Therapeutic antibodies and small‑molecule agents targeting tau protein aggregates for neurodegeneration | — |
| 18 | TETmedical Developer of nanomedicine in-vitro diagnostics for high-consequence disease decision making | $2M | 31 mo ago | — | Roy Cohen Co-Founder | 4 patents Tethered enzyme biosensor platforms for enzymatic activity detection of clinical biomarkers | — |
| 19 | iQure Pharma Developer of therapeutics for neuropathic pain | $2M | 19 mo ago | 6 | Peter Schiemann Co-Founder & Member Board Of Directors | — | 1 launch |
| 20 | Brighton Biotech Small molecule drug and vaccines for CNS disorders & infectious diseases | $2M | 140 mo ago | — | — | — | — |
| 21 | NanoNewron Developer of humanized biologics to treat central nervous system diseases | $1000K | 15 mo ago | — | Luciano Adamio Founder | — | — |
| 22 | MentiNova Drug for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease | $500K | 162 mo ago | — | Maral Mouradian Co-Founder & President | 2 patents Pharmaceutical formulations that mitigate sedation side effects in therapeutic compounds | — |
| 23 | Zena Therapeutics Developer of therapeutics to treat alcohol use disorder | $364K | 18 mo ago | 2 | — | — | 1 award |
| 24 | Couragene Developer of gene and biological therapies through novel delivery platforms | $340K | 22 mo ago | 2 | Amy Liao Co-Founder | — | — |
| 25 | Neuroview Technology Developer of a subcutaneous implant to monitor epilepsy | $304K | 31 mo ago | 6 | Daniel Friedman Co-Founder | — | — |
| 26 | OculoMotor Technologies Virtual reality based therapy for binocular vision dysfunctions patients | $225K | 85 mo ago | 7 | Chang Yaramothu Co-Founder & CEO & CTO | — | — |
| 27 | Celvive therapeutics Early-stage biotech company developing mesenchymal stem cell therapy for chronic spinal cord injury patients. | $175K | 187 mo ago | 3 | Hatem Sabaawy Founder | — | — |
| 28 | Brainmarc Mobile health platform for monitoring mental activity | $111K | 82 mo ago | 2 | Goded Shahaf Co-Founder | — | — |
Top 12 Neurology companies in New Jersey
#1
Public · Basking Ridge, New Jersey · founded 2005 · 58 employees$121.4Mraised▾
Developer of non-invasive vagus nerve stimulation devices. The company has developed gammaCore a hand-held portable device that produces a mild electrical signal to treat migraines and cluster headaches. It is also, used for epilepsy, gastric motility disorders, depression, and anxiety.
- Oct 2025Post IPO$1.9M
- Jun 2024Post IPO$7.8M
- Aug 2023Post IPO$750K
- Oct 2021Post IPO$192K
#2
Public · Warren, New Jersey · founded 2005 · 285 employees$9.1Mraised▾
Developer of small molecule-based therapeutics for the treatment of CNS diseases. The company uses proprietary PharmFilm technology to develop a portfolio of treatments for CNS disorders. The company's product pipeline inlcudes "Libervant" for seizures, AQST-108 for the treatment of severe allergies, AQST-305 for acromegaly and neuroendocrine tumors, and many more.
- Aug 2025Post IPO$75M
- Jul 2019Conventional Debt$70M
- Apr 2018Series A$9.1M
- Aug 2016Conventional Debt$50M
#3
Funding Raised · Monmouth Junction, New Jersey · founded 2009 · 13 employees$21.8Mraised▾
Developer of minimally invasive diagnostic tests. It has developed a proprietary targeted approach for early detection and monitoring of neurodegenerative diseases based on quantitative analysis of brain-enriched microRNA pairs in plasma. The company has collaborated with Janssen Neuroscience to investigate how DiamiR technology can be used in the context of clinical development of a therapeutic agent for the treatment of neurodegenerative disease. Its lead product CogniMir is aimed at early detection of circulating miRNAs for the early detection of Alzheimer's disease.
- May 2025Grant (prize money)$9.5M
- Sep 2020Grant (prize money)$609.5K
- Sep 2019Grant (prize money)$345K
- Jun 2016Grant (prize money)$224.6K
#4
Series A · Bridgewater, New Jersey · founded 2016 · 2 employees$12.4Mraised▾
Developer of digital therapeutics for neuromuscular conditions. The products consist of wearable wireless EMG sensors connected to an app. The app is used to command the product to provide treatment protocol or games for muscle relaxation, movement coordination, and neuro-muscular re-education.
- Jun 2025Series A$2.1M
- Oct 2024Series A$75K
- Jun 2024Series A$5.5M
- Aug 2023Series A$3.3M
#5
Series B · Princeton, New Jersey · founded 2020$15.8Mraised▾
Provider of specialty pharmaceutical company that focuses on responsible pain management. It offers RoxyBond formulated with SentryBond technology,is a abuse-deterrent immediate-release oxycodone hydrochloride for opioid abuse deterrence and for treating pain.
- Apr 2025Series B$15.8M
#6
Public · South Plainfield, New Jersey · founded 1998 · 995 employees$248.1Mraised▾
Developer of small molecule drugs for the treatment of rare diseases. The company's lead product Ataluren is an orally administered small-molecule drug for the treatment of cystic fibrosis and Duchenne muscular dystrophy caused by nonsense mutations. Also, developing anticancer and antibacterial drugs.
- May 2023Post IPO$35.9M
- May 2020Post IPO$140.9M
- Sep 2019Post IPO$250M
- Mar 2018Post IPO$108.2M
#7
Funding Raised · Union, New Jersey · founded 2022$999.7Kraised▾
Developer of humanized biologics to treat central nervous system diseases. The company utilizes nanobody technologies for neuroinflammatory and neurodegenerative conditions. It targets pathologies affecting the central nervous system.
- May 2025Grant (prize money)$499.8K
- Jan 2025Grant (prize money)$499.8K
#8
Series B · Monmouth Junction, New Jersey · founded 2000 · 441 employees$125Mraised▾
Innovating transformative treatments for ADHD, pain, and CNS disorders. This biopharmaceutical company focuses on developing and commercializing innovative medicines addressing unmet patient needs in neuroscience and other therapeutic categories. They utilize proprietary science and technology to create differentiated therapeutic approaches, including novel mechanisms and investigational compounds. Their commitment extends to delivering high-quality, patient-friendly therapeutics with maximum benefit. They have a robust pipeline of investigational therapies targeting ADHD, pain, addiction, and other central nervous system diseases. They are dedicated to advancing the science of pain biology and improving the lives of patients through innovation and a culture of care.
- Sep 2023Grant (prize money)—
- Sep 2018Series B$125M
- Sep 2018Conventional Debt$125M
#9
Series A · Princeton, New Jersey · founded 2019 · 6 employees$2.1Mraised▾
Developer of therapeutics for neuropathic pain. The company's pipeline include iQ-007 a positive allosteric modulator for EAAT2 found in epilepsy, and iQ-008 acts on pain-relevant molecular targets Cav1.2 channel, Sodium ion channels, and TRPV1 receptor for neuropathic pain.
#10
Public · Englewood Cliffs, New Jersey · founded 2010 · 2 employees$10.1Mraised▾
Manufacturer of neurological drugs
- Jun 2024Post IPO$2.3M
- Feb 2021Post IPO$4.3M
- May 2020Post IPO$2.4M
- Dec 2019Post IPO$115K
#11
Funding Raised · Princeton, New Jersey · founded 2021 · 2 employees$364.4Kraised▾
Developer of therapeutics to treat alcohol use disorder. It offers medicinal and natural products to create drugs for poly-substance abuse, anxiety disorders, alcohol, and substance use.
- Feb 2025Grant (prize money)$364.4K
#12
Series B · Camden, New Jersey · founded 2010 · 5 employees$8.1Mraised▾
Developer of the diagnostic test for neurodegenerative diseases. The test is based on the detection of disease-specific autoantibodies as blood biomarkers associated with Alzheimer's and Parkinson's disease.
- Oct 2023Conventional Debt$3.5M
- Dec 2022Series B$4.6M
- Dec 2019Series A$3.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
- Boston Scient Neuromodulation865
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers75
- Pacesetter67
- Cyberonics54
- Axonics43
- PREC Neuroscience43
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.